An observational evaluation of prescribing of fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist (ICS/LABA): fluticasone propionate / formoterol (FP/FOR) and adverse events in routine primary care at 18-months and 36-months post launch

First published 08/02/2016

Last updated 23/04/2024

EU PAS number:

EUPAS12330

Study

Finalised

Documents

Study protocol

Study results

160714_R02213_Flutiform offlabel and AEs_Stage 1_Final report_v2.0 (1)

English (6.22 MB - PDF)View document

160829_R02213_Flutiform offlabel and AEs_Stage 2_Final report_v1.1 (1)

English (5.12 MB - PDF)View document

Study report

Other information

ENCePP Seal

ENCePP Seal documents

Secondary tabs